Satoshi Konagai
Industry Advisor at M
San Francisco Bay Area
Overview
Work Experience
Investment Lead
2024 - Current
Associate Investment Director
2023 - 2024
Senior Investment Manager
2020 - 2023
Industry Advisor
2024
Board Observer
2024
Board Director
2024
Board Director
2023
Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
Raised $31,000,000.00 from Longwood Fund, Astellas Venture Management, Sante Ventures, Alexandria Venture Investments and DCVC Bio.
Board Observer
2023
Board Director
2023
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Raised $154,870,000.00 from The Column Group, Eventide Management Partners, Euclidean Capital, Ono Venture Investment, Astellas Venture Management, Third Rock Ventures, Schroders Capital, Eisai, Mirae Asset and Amgen Ventures.
Board Observer
2023
Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Raised $75,000,000.00 from Medical Excellence Capital, Astellas Venture Management, Sanofi Ventures, RA Capital Management and RA Capital Management.
Board Observer
2022
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Raised $70,000,000.00 from Emerson Collective, UTokyo Innovation Platform, Pfizer Venture Investments, Astellas Venture Management, Alta Partners, Alexandria Venture Investments, Longwood Fund and Insight Partners.
Board Observer
2021 - 2022
Novel drug delivery targeting – minimising healthy tissue damage.